Liver Transplant — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Orthotopic liver transplantation (OLT) is the definitive surgical treatment for end-stage liver disease and acute liver failure, replacing the recipient's diseased liver with a healthy organ from a deceased or living donor. The liver is the only solid organ capable of complete regeneration — a property that enables living donor transplantation, in which a healthy donor donates 50–70% of their liver volume (typically the right lobe for adult recipients), with both donor and recipient livers regenerating to full size within 4–8 weeks through hepatocyte proliferation. Deceased donor transplants use either donation after brain death (DBD) organs — the traditional source — or donation after circulatory death (DCD) organs, which have expanded the donor pool significantly over the past decade. The allocated liver must be implanted within a cold ischemia time of ideally less than 12–16 hours (DBD) or 6–10 hours (DCD) to maintain graft viability. Machine perfusion technology (normothermic ex-vivo machine perfusion, or 'liver on a pump') is increasingly used to assess marginal grafts, extend preservation times, and recondition DCD livers before transplantation — an innovation that is rapidly expanding the functional donor pool. Liver transplantation is performed at specialist hepatobiliary centres with dedicated multidisciplinary transplant teams: hepatologists, transplant surgeons, anaesthetists, intensive care physicians, transplant coordinators, and specialist nurses.

Liver transplantation is indicated when liver disease is expected to cause death within a defined time frame without transplantation, when the quality of life from hepatic complications (encephalopathy, refractory ascites, variceal bleeding) is unacceptable, or when hepatocellular carcinoma meets transplantation criteria offering cure. The MELD score (Model for End-stage Liver Disease) — calculating a 90-day mortality probability from bilirubin, INR, and creatinine — is the primary allocation tool; transplantation is typically listed at MELD 15 or above. Common chronic liver disease indications include: cirrhosis from non-alcoholic fatty liver disease (NAFLD/NASH — now the leading indication in many countries), alcohol-related liver disease (ALD — requiring a minimum 6-month abstinence in most programmes), viral hepatitis-related cirrhosis (HBV, HCV — HCV is now eradicated pre-transplant with direct-acting antivirals), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis. Acute indications include acute liver failure from paracetamol (acetaminophen) toxicity, viral hepatitis, or drug reactions meeting King's College criteria. Hepatocellular carcinoma (HCC) within the Milan criteria (single tumour ≤5 cm, or up to 3 tumours ≤3 cm each, no vascular invasion) achieves 5-year post-transplant survival of 70–75% — comparable to non-HCC transplantation — as the transplant removes both the cancer and the cirrhotic field from which new tumours would arise. Metabolic liver diseases (Wilson's disease, hereditary haemochromatosis, alpha-1 antitrypsin deficiency) are cured by transplantation.

Liver transplantation is a complex major abdominal operation performed under general anaesthesia requiring 6–8 hours. The recipient undergoes a hepatectomy — complete removal of the diseased liver while maintaining vascular continuity via a veno-venous bypass that returns blood from the portal system and inferior vena cava to the systemic circulation during the anhepatic phase, preventing venous congestion and cardiovascular instability. The donor liver is implanted in the standard orthotopic position: four vascular anastomoses are sequentially performed using monofilament sutures — the suprahepatic inferior vena cava (or piggyback technique preserving the recipient IVC), the infrahepatic IVC, the portal vein, and the hepatic artery. Arterial reconstruction is the most technically demanding anastomosis, performed under surgical loupe magnification, as hepatic artery thrombosis (HAT) — the most common technical complication — occurs in 3–5% of cases and can cause graft failure. The biliary anastomosis is constructed as a duct-to-duct choledochocholedochostomy over a T-tube (removed at 3 months) in patients with normal bile ducts, or a Roux-en-Y hepaticojejunostomy in patients with PSC or biliary atresia. Reperfusion of the donor liver is a critical moment requiring anaesthetic management of the reperfusion syndrome (haemodynamic instability, hyperkalaemia, and cardiac arrhythmias from the initial flush of cold preservation solution). Intraoperative coagulation is managed with fresh frozen plasma, cryoprecipitate, and platelet transfusions as needed. Blood losses of 2–10 litres are typical; cell salvage and tranexamic acid reduce transfusion requirements.

Liver transplantation is life-saving for patients with end-stage liver disease or acute liver failure who have no other treatment options. One-year post-transplant patient survival is 85–92% at accredited centres; 5-year survival is 70–80%; 10-year survival is 60–65% — rates that reflect both the transplant procedure and the patient's underlying co-morbidity rather than a limitation of the transplant itself. Graft survival (freedom from retransplantation) parallels patient survival in most series. For HCC within Milan criteria, transplantation provides 5-year survival of 70–75% with a 10–15% recurrence rate — outcomes superior to resection in the setting of underlying cirrhosis. Functional outcomes are excellent: the majority of recipients achieve full restoration of liver synthetic function (normalised INR, albumin, and bilirubin) within weeks. Quality of life improves dramatically: patients previously disabled by ascites, encephalopathy, and muscle wasting typically return to near-normal function by 6–12 months. Employment rates of 40–70% are reported at 5 years in working-age recipients, though returning to pre-illness employment requires oncological and metabolic stability, rehabilitation, and employer support. Long-term immunosuppression enables graft acceptance but requires lifelong management. The advent of curative HCV treatment (direct-acting antivirals) before transplantation has eliminated viral recurrence — previously the leading cause of graft loss — transforming outcomes for HCV-related cirrhosis.

Liver transplantation carries perioperative and long-term risks reflecting the complexity of the surgery and the need for lifelong immunosuppression. Primary non-function (the transplanted liver never works) occurs in approximately 2–5% of cases and is the most devastating early complication — it requires emergency retransplantation within 72 hours or is fatal. Hepatic artery thrombosis (HAT) occurs in 3–5% of adult and up to 10% of paediatric transplants; it typically manifests as bile duct ischaemia and bilomas ('biliary complications' in 10–30% of all recipients), which may require endoscopic or surgical management. Acute cellular rejection affects 20–30% of recipients in the first year — immunologically mediated attack by recipient T-cells against donor hepatocytes — and is usually managed successfully with high-dose corticosteroid boluses; it rarely leads to graft loss. Chronic rejection — progressive bile duct loss and graft fibrosis — affects approximately 3–5% and may require retransplantation. Infections are a major cause of morbidity and mortality, particularly in the first year: bacterial infections in the first month (wound infection, cholangitis, pneumonia); CMV and EBV infections in months 1–6; and late opportunistic infections (Pneumocystis, aspergillosis) in recipients with ongoing high-level immunosuppression. Long-term immunosuppression risks include: chronic kidney disease (calcineurin inhibitor nephrotoxicity affects over 20% at 10 years); de novo malignancy (particularly skin cancer and post-transplant lymphoproliferative disorder, PTLD); cardiovascular disease, hypertension, and diabetes mellitus from corticosteroids and calcineurin inhibitors; and metabolic bone disease (osteoporosis from steroid use).

Immediate post-operative care takes place in the liver transplant intensive care unit. Most patients are extubated within 12–24 hours. The early post-operative course is dominated by monitoring for graft function (synthetic tests: INR, albumin, bile production), haemodynamic stability, and renal function. ICU stay is typically 3–7 days; total hospitalisation 2–4 weeks. Immunosuppression is started peri-operatively: the standard triple regimen comprises tacrolimus (calcineurin inhibitor — the cornerstone of post-transplant immunosuppression), mycophenolate mofetil, and prednisolone. Tacrolimus levels are monitored by trough blood concentration regularly — target levels are highest in the first months and reduced over 12–24 months as the risk of rejection decreases. Prednisolone is tapered and withdrawn in many patients by 3–12 months post-transplant to reduce its metabolic side effects. Prophylaxis against opportunistic infections includes co-trimoxazole (for Pneumocystis, 6–12 months), valganciclovir (for CMV in seropositive donor/recipient combinations, 3–6 months), and fluconazole or nystatin (for candida prophylaxis). Diet: a nutritious diet with adequate protein and calories is critical in the first year; sodium restriction for residual fluid retention; alcohol is permanently contraindicated. Driving is prohibited for a minimum of 6 weeks and until medical fitness is confirmed. Return to light work at 3–6 months; full activity at 6–12 months. Lifelong hepatology and transplant follow-up is mandatory for immunosuppression management, monitoring for rejection, infection, and malignancy, and management of long-term metabolic complications.